Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-10-09 5:00 pm Purchase | 2026-10-07 | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 10,185,961 9.990% | 518,760 (+5.37%) | Filing History |
| 2026-10-01 4:05 pm Purchase | 2026-09-24 | 13G | SPYRE THERAPEUTICS, INC SYRE | Paradigm BioCapital Advisors LP | 4,457,450 5.100% | 4,457,450 (New Position) | Filing History |
| 2026-08-14 5:22 pm Unchanged | 2026-06-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | Perceptive Advisors LLC | 4,319,496 4.900% | 0 (Unchanged) | Filing History |
| 2026-08-14 08:10 am Purchase | 2026-06-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | RTW Investments, LP | 4,251,996 4.800% | 630,000 (+17.39%) | Filing History |
| 2026-06-23 9:45 pm Purchase | 2026-06-23 | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 9,667,201 9.990% | 650,499 (+7.21%) | Filing History |
| 2026-04-22 4:00 pm Purchase | 2026-04-15 | 13G | SPYRE THERAPEUTICS, INC SYRE | Perceptive Advisors LLC | 4,319,496 5.000% | 1,744,773 (+67.77%) | Filing History |
| 2026-04-20 6:00 pm Purchase | 2026-04-16 | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 9,016,702 9.990% | 909,820 (+11.22%) | Filing History |
| 2026-03-27 1:17 pm Sale | 2026-03-13 | 13G | SPYRE THERAPEUTICS, INC SYRE | VANGUARD GROUP INC | 0 0.000% | -3,066,586 (Position Closed) | Filing History |
| 2026-02-17 4:15 pm Sale | 2025-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | TANG CAPITAL MANAGEMENT, LLC | 1,892,200 2.400% | -1,307,800 (-40.87%) | Filing History |
| 2025-10-17 5:00 pm Purchase | 2025-10-15 | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 8,106,882 9.990% | 3,598,303 (+79.81%) | Filing History |
| 2025-07-29 2:40 pm Purchase | 2025-06-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | VANGUARD GROUP INC | 3,066,586 5.080% | 3,066,586 (New Position) | Filing History |
| 2025-07-16 7:02 pm Purchase | 2025-06-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | BlackRock, Inc. BLK | 3,962,635 6.600% | 1,299,488 (+48.80%) | Filing History |
| 2025-05-01 4:15 pm Purchase | 2025-04-24 | 13G | SPYRE THERAPEUTICS, INC SYRE | TANG CAPITAL MANAGEMENT, LLC | 3,200,000 5.300% | 3,200,000 (New Position) | Filing History |
| 2025-02-14 6:06 pm Unchanged | 2024-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 4.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Perceptive Advisors LLC | 2,574,723 4.400% | -297,824 (-10.37%) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | RTW Investments, LP | 3,621,996 6.200% | 1,389,236 (+62.22%) | Filing History |
| 2024-11-14 5:50 pm Sale | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 5.300% | -1,049,066 (-28.09%) | Filing History |
| 2024-11-14 4:33 pm Purchase | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | Perceptive Advisors LLC | 2,872,547 5.700% | 265,868 (+10.20%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | Commodore Capital LP | 1,988,084 3.900% | 54,000 (+2.79%) | Filing History |
| 2024-11-14 09:44 am Sale | 2024-09-30 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Deep Track Capital, LP | 1,000,000 1.970% | -1,184,440 (-54.22%) | Filing History |